Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired 15,786 shares of Pacira BioSciences, Inc. for approximately $392,000 in the first quarter, reflecting a growing interest from institutional investors in the company.
• Pacira BioSciences' stock has seen a 4.6% increase and currently has a market cap of $1.02 billion, with shares trading around $22.07.
• Recent analyst reports have upgraded Pacira BioSciences, with a consensus rating of "Moderate Buy" and a price target of $25.75, indicating expectations for future growth.

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 15,786 shares of the company's stock, valued at approximately $392,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Raymond James Financial Inc. purchased a new position in shares of Pacira BioSciences in the fourth quarter worth approximately $190,000. American Century Companies Inc. lifted its position in shares of Pacira BioSciences by 46.6% in the 4th quarter. American Century Companies Inc. now owns 135,592 shares of the company's stock valued at $2,555,000 after acquiring an additional 43,123 shares in the last quarter. LPL Financial LLC acquired a new position in Pacira BioSciences in the 4th quarter worth approximately $251,000. Norges Bank purchased a new position in Pacira BioSciences during the 4th quarter worth approximately $2,405,000. Finally, Wellington Management Group LLP grew its position in Pacira BioSciences by 3.4% during the 4th quarter. Wellington Management Group LLP now owns 470,191 shares of the company's stock worth $8,858,000 after purchasing an additional 15,542 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company's stock.

Pacira BioSciences Stock Up 4.6%

Shares of Pacira BioSciences stock opened at $22.07 on Monday. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of -9.68 and a beta of 0.48. The stock has a 50-day simple moving average of $23.83 and a 200-day simple moving average of $24.59. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $27.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.41 and a quick ratio of 1.99.

Analyst Ratings Changes

PCRX has been the subject of a number of research analyst reports. Wall Street Zen upgraded Pacira BioSciences from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Needham & Company LLC dropped their price target on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Truist Financial raised Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 price objective for the company in a research note on Friday, July 25th. Finally, HC Wainwright lifted their target price on Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research note on Tuesday, April 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $25.75.

Insider Transactions at Pacira BioSciences

In other Pacira BioSciences news, SVP Lauren Riker sold 5,578 shares of the business's stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $26.21, for a total value of $146,199.38. Following the completion of the sale, the senior vice president directly owned 59,564 shares of the company's stock, valued at $1,561,172.44. The trade was a 8.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 6.40% of the stock is owned by company insiders.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.